An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease; Coronary disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 25 Feb 2026 New trial record